Tirzepatide (Mounjaro/Zepbound) already delivers 15-22% body weight loss through dual GIP/GLP-1 receptor activation - making it one of the most powerful single-agent options available
BI 456906 (survodutide), developed as a dual agonist for GLP-1 and glucagon receptors for the treatment of obesity and NASH, is structurally modified from glucagon [109]
If you're pregnant or planning to become pregnant, discuss this with your healthcare provider to determine the best course of action
But once a young girl enters, what I think of as, the Facebook Loop of Shame, they are not only seeing damaging ads, but they are stuck in a never-ending loop of before and after pictures, body-composition advice, plate-to-plate calorie comparisons, advice on making their waste smaller, how to prevent wrinkles, how to change the shape of the face with injections, how to make the face look more uplifted without the use of injections, and on and on and on
Earlier Phase 2 data corroborated these findings, showing that up to 82% of participants achieved a target HbA1c of less than 6.5%
Remember, successful weight loss is a journey requiring commitment to lifestyle modifications beyond medication